NEW YORK (GenomeWeb) – Ventana today said that it is collaborating with MedImmune to develop a companion diagnostic for a drug MedImmune is developing for non-small cell lung cancer.

The companion diagnostic will be an immunohistochemistry assay that aims to identify patients who express programmed cell death ligand 1. MedImmune is developing an anti-PD-L1 therapy dubbed MEDI4736, which is currently in clinical studies. The drug firm will use the Ventana assay in that study.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.